|
1
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar
|
|
2
|
Gallagher EJ and LeRoith D: Insulin,
insulin resistance, obesity, and cancer. Curr Diab Rep. 10:93–100.
2010. View Article : Google Scholar
|
|
3
|
Martin-Castillo B, Vazquez-Martin A,
Oliveras-Ferraros C and Menendez JA: Metformin and cancer: doses,
mechanisms and the dandelion and hormetic phenomena. Cell Cycle.
9:1057–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalez-Angulo AM and Meric-Bernstam F:
Metformin: a therapeutic opportunity in breast cancer. Clin Cancer
Res. 16:1695–1700. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones RG, Plas DR, Kubek S, et al:
AMP-Activated protein kinase induces a p53-dependent metabolic
checkpoint. Mol Cell. 18:283–293. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation - implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kisfalvi K, Sinnett-Smith J, Eibl G and
Rozengurt E: Metformin inhibits growth of human pancreatic cancer
cells in vitro and in vivo. Pancreas. 38:1016–1017. 2009.
|
|
9
|
Bodmer M, Becker C, Jick SS and Meier CR:
Metformin does not alter the risk of lung cancer: a case-control
analysis. Lung Cancer. 78:133–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of metformin is not associated with a decreased risk
of colorectal cancer: a case-control analysis. Cancer Epidemiol
Biomarkers Prev. 21:280–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buzzai M, Jones RG, Amaravadi RK, et al:
Systemic treatment with the antidiabetic drug metformin selectively
impairs p53-deficient tumor cell growth. Cancer Res. 67:6745–6752.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reuter CW, Morgan MA and Bergmann L:
Targeting the Ras signaling pathway: a rational, mechanism-based
treatment for hematologic malignancies? Blood. 96:1655–1669.
2000.PubMed/NCBI
|
|
13
|
Cox AD and Der CJ: Ras family signaling:
therapeutic targeting. Cancer Biol Ther. 1:599–606. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friday BB and Adjei AA: K-ras as a target
for cancer therapy. Biochim Biophys Acta. 1756:127–144.
2005.PubMed/NCBI
|
|
15
|
Legaspi A, Jeevanandam M, Starnes HF Jr
and Brennan MF: Whole body lipid and energy metabolism in the
cancer patient. Metabolism. 36:958–963. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blum R and Kloog Y: Tailoring Ras-pathway
- inhibitor combinations for cancer therapy. Drug Resist Updat.
8:369–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skolnik EY, Batzer A, Li N, et al: The
function of GRB2 in linking the insulin receptor to Ras signaling
pathways. Science. 260:1953–1955. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Noguchi T, Matozaki T, Horita K, Fujioka Y
and Kasuga M: Role of SH-PTP2, a protein-tyrosine phosphatase with
Src homology 2 domains, in insulin-stimulated Ras activation. Mol
Cell Biol. 14:6674–6682. 1994.PubMed/NCBI
|
|
19
|
Desbois-Mouthon C, Cadoret A, Blivet-Van
Eggelpoël MJ, et al: Insulin and IGF-1 stimulate the beta-catenin
pathway through two signalling cascades involving GSK-3beta
inhibition and Ras activation. Oncogene. 20:252–259. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Medema RH, de Vries-Smits AM, van der Zon
GC, Maassen JA and Bos JL: Ras activation by insulin and epidermal
growth factor through enhanced exchange of guanine nucleotides on
p21ras. Mol Cell Biol. 13:155–162. 1993.PubMed/NCBI
|
|
21
|
Lehman TA, Bennett WP, Metcalf RA, et al:
p53 mutations, ras mutations and p53-heat shock 70 protein
complexes in human lung carcinoma cell lines. Cancer Res.
51:4090–4096. 1991.PubMed/NCBI
|
|
22
|
Watanabe M, Nobuta A, Tanaka J and Asaka
M: An effect of K-ras gene mutation on epidermal growth factor
receptor signal transduction in PANC-1 pancreatic carcinoma cells.
Int J Cancer. 67:264–268. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Oliveras-Ferraros C, Cufi S, Queralt B, et
al: Cross-suppression of EGFR ligands amphiregulin and epiregulin
and de-repression of FGFR3 signalling contribute to cetuximab
resistance in wild-type KRAS tumour cells. Br J Cancer.
106:1406–1414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Iivanainen E, Lauttia S, Zhang N, et al:
The EGFR inhibitor gefitinib suppresses recruitment of pericytes
and bone marrow-derived perivascular cells into tumor vessels.
Microvasc Res. 78:278–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartrons R and Caro J: Hypoxia, glucose
metabolism and the Warburg’s effect. J Bioenerg Biomembr.
39:223–229. 2007.
|
|
26
|
Feig LA and Buchsbaum RJ: Cell signaling:
life or death decisions of ras proteins. Curr Biol. 12:R259–R261.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ferla R, Haspinger E and Surmacz E:
Metformin inhibits leptin-induced growth and migration of
glioblastoma cells. Oncol Lett. 4:1077–1081. 2012.PubMed/NCBI
|
|
28
|
Adjei AA: Blocking oncogenic Ras signaling
for cancer therapy. J Natl Cancer Inst. 93:1062–1074. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang W and Guan KL: AMP-activated protein
kinase and cancer. Acta Physiol (Oxf). 196:55–63. 2009. View Article : Google Scholar
|
|
30
|
Carling D: AMP-activated protein kinase:
balancing the scales. Biochimie. 87:87–91. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mahoney CL, Choudhury B, Davies H, et al:
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC
with increased sensitivity to MAPK and mTOR signalling inhibition.
Br J Cancer. 100:370–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ben Sahra I, Regazzetti C, Robert G, et
al: Metformin, independent of AMPK, induces mTOR inhibition and
cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372.
2011.PubMed/NCBI
|
|
33
|
Kalender A, Selvaraj A, Kim SY, et al:
Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cox AD and Der CJ: Farnesyltransferase
inhibitors: promises and realities. Curr Opin Pharmacol. 2:388–393.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li D: Metformin as an antitumor agent in
cancer prevention and treatment. J Diabetes. 3:320–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
